A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04782258 |
|
Recruitment Status :
Recruiting
First Posted : March 4, 2021
Last Update Posted : November 1, 2023
|
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Autosomal Recessive Polycystic Kidney (ARPKD) | Drug: Tolvaptan Suspension Drug: Tolvaptan Tablets | Phase 3 |
This study is a multinational, multicenter, open-label, non-randomized trial. The study consist of three periods: Screening Period, Treatment period and Follow-up period.
Tolvaptan has been demonstrated to delay the decline of kidney function in adults with rapidly progressing ADPKD (CKD stages 1 to 4), a closely related indication to ARPKD, as measured by estimated glomerular filtration rate (eGFR) and Total Kidney Volume (TKV).
Participants in this study will be assigned to tolvaptan and followed for 18 months over the course of the study.
The overall trial duration is expected to be approximately 3.5 years.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 10 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD) |
| Actual Study Start Date : | July 15, 2022 |
| Estimated Primary Completion Date : | April 27, 2026 |
| Estimated Study Completion Date : | April 27, 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Polycystic kidney disease
MedlinePlus related topics:
Kidney Diseases
Drug Information
available for:
Tolvaptan
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Tolvaptan Suspension
Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.
|
Drug: Tolvaptan Suspension
Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. |
|
Experimental: Tolvaptan Tablets
Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets. Treatment duration is 18 months.
|
Drug: Tolvaptan Tablets
Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets. |
Primary Outcome Measures :
- Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Enrollment up to 7 days post last dose ]
Secondary Outcome Measures :
- Annual rate of change of eGFR (by Schwartz formula) from baseline to post-treatment after 18 months of treatment [ Time Frame: From Enrollment to 18 months ]
- Change from baseline of eGFR (by Schwartz formula) while on treatment at Months 1, 6, 12, and 18 [ Time Frame: 1 month, 6 months, 12 months, and 18 months ]
- The percentage of subjects that will receive renal replacement therapy (RRT) by 18 months. [ Time Frame: From Enrollment to 18 months ]
- The amount of time between enrollment and 18 months that a subject requires renal replacement therapy (RRT). [ Time Frame: From enrollment to 18 months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 28 Days to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female subjects between 28 days and less than 18 years of age, with clinical features that are consistent with a diagnosis of ARPKD.
- Ability for parent/legal guardian to provide written, informed consent prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial. Ability to provide written informed assent from all subjects old enough per local laws to provide assent.
Exclusion Criteria:
- Premature birth (≤ 32 weeks gestational age) for infants 28 days to < 12 weeks of age.
- Anuria or RRT defined as intermittent or continuous hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration or history of kidney transplantation.
- Evidence of syndromic conditions associated with renal cysts (other than ARPKD).
- Abnormal liver function tests including ALT and AST, > 1.2 × ULN (upper limit of normal).
- Has splenomegaly or portal hypertension (HTN).
- Parents with renal cystic disease.
- Receiving chronic diuretic that could not be adjusted after tolvaptan initiation.
- Cannot be monitored for fluid balance.
- Has or at risk of having sodium and potassium electrolyte imbalances, as determined by the investigator.
- Has or at risk of having significant hypovolemia as determined by investigator.
- Clinically significant anemia, as determined by investigator.
- Platelets < 50000 µL.
- Severe systolic dysfunction defined as ejection fraction < 14%.
- Serum sodium levels < 130 mmol/L or >145 mmol/L.
- Taking any other experimental medications.
- Require ventilator support.
- Taking medications known to induce CYP3A4 (CYP = Cytochrome P).
- Having an infection including viral that would require therapy disruptive to IMP dosing.
- Females who are breast-feeding or who have a positive pregnancy test result prior to receiving IMP.
- Subjects with a history of substance abuse (within the last 6 months).
- Subjects who have bladder dysfunction and/or difficulty voiding.
- Subjects taking a vasopressin agonist (eg, desmopressin).
- Subjects with a history of persistent noncompliance with antihypertensive or other important medical therapy.
- Subjects taking medications or having concomitant illnesses likely to confound endpoint assessments, including taking approved (ie, marketed) therapies for the purpose of affecting PKD cysts such as tolvaptan, vasopressin antagonists, anti-sense ribonucleic acid (RNA) therapies, rapamycin, sirolimus, everolimus, or somatostatin analogs (ie, octreotide, sandostatin).
- Received or are scheduled to receive a liver transplant.
- History of cholangitis within the last 6 months.
- Has findings consistent with clinically significant portal hypertension (eg, varices, variceal bleeding, hypersplenism indicated by thrombocytopenia).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04782258
Contacts
| Contact: Leslyn Hermonstine | 240.683.3157 | Leslyn.Hermonstine@otsuka-us.com | |
| Contact: Linda Cappiello | +1 (609) 6084545 | linda.cappiello-cw@otsuka-us.com |
Locations
Show 19 study locations
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Investigators
| Study Director: | Olga Sergeyeva, MD | Olga.Sergeyeva@otsuka-us.com |
| Responsible Party: | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| ClinicalTrials.gov Identifier: | NCT04782258 |
| Other Study ID Numbers: |
156-201-00307 2020-005992-10 ( EudraCT Number ) |
| First Posted: | March 4, 2021 Key Record Dates |
| Last Update Posted: | November 1, 2023 |
| Last Verified: | October 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
|
ARPKD TOLVAPTAN Polycystic Kidney Disease Autosomal Recessive Polycystic Kidney Disease |
Adolescent Renal Cysts Oligohydramnios Anhydramnios |
Additional relevant MeSH terms:
|
Kidney Diseases Polycystic Kidney Diseases Polycystic Kidney, Autosomal Recessive Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases Kidney Diseases, Cystic |
Abnormalities, Multiple Congenital Abnormalities Ciliopathies Genetic Diseases, Inborn Tolvaptan Antidiuretic Hormone Receptor Antagonists Molecular Mechanisms of Pharmacological Action Natriuretic Agents Physiological Effects of Drugs |